

February 27, 2008

MEMORANDUM TO: Those on the Enclosed List

FROM: Eric Duncan, Chief */RA/*
Plant Support Branch
Division of Reactor Safety

SUBJECT: FINAL GUIDANCE ON THE USE OF POTASSIUM IODIDE (KI)
BY NRC EMPLOYEES

The NRC's guidance on the use of potassium iodide (KI) remains unchanged from the previous information that we distributed in November of 2002, December of 2003, January of 2005, and July of 2006, and that was presented to you during your initial employee orientation. The guidance can be found in NRC Management Directive 10.131, "Protection of NRC Employees Against Ionizing Radiation," and is also provided in the following:

- (1) Memorandum from Roy P. Zimmerman, dated July 3, 2002 (ML020840147);
- (2) FDA Guidance - Potassium Iodide as a Thyroid Blocking Agent (ML020840164);
- (3) Summary of Comments on Draft Guidance for Use of Potassium Iodide by NRC Employees, issued December 14, 2001 (ML020380554); and
- (4) NRC Use of Potassium Iodide (KI) During an Emergency (ML0208401580).

Based on comments received from the staff over the past several years, we are not providing a copy of the guidance documents with this memorandum. Instead, we have provided the ADAMS locations for the referenced documents so that you may obtain them for additional review, as applicable. We are also providing the location for the "Region III Incident Response General Overview Training" Handout (see attachment), which we encourage you to review.

Please confirm your receipt of this memorandum by completing and returning the "**POTASSIUM IODIDE INFORMATION ACKNOWLEDGMENT FORM**" that we have attached to this memorandum to Desiree Smith within 21 days of your receipt of this memorandum. Annually, we will continue to provide you with a copy of this guidance, along with any revisions, and request a confirmation that you have received it.

Enclosure: As stated

CONTACTS: Desiree Smith, DRS
(630) 829-9853

If you have any questions about the guidance, please direct them to Desiree Smith at (630) 829-9853 or me at (630) 829-9757. Although the NRC Regional Administrator, in consultation with the Headquarters Executive Team, will determine when to recommend KI to Resident Inspectors and Site Team Members, its use is voluntary based on input from your personal physician.

We have distributed four packets of KI to each resident site (fourteen tablets each) and recommend that they be stored at the resident office onsite. The effectiveness of KI as a thyroid protective agent is only slightly reduced if taken shortly after exposure to radioiodine (such as traveling through a release plume on the way to the site). Residents, please store these packets in accordance with the recommendations provided on the label. Please discard any outdated bottles by disposal into a sanitary sewer system.

If you have any questions about the guidance, please direct them to Desiree Smith at (630) 829-9853 or me at (630) 829-9757. Although the NRC Regional Administrator, in consultation with the Headquarters Executive Team, will determine when to recommend KI to Resident Inspectors and Site Team Members, its use is voluntary based on input from your personal physician.

We have distributed four packets of KI to each resident site (fourteen tablets each) and recommend that they be stored at the resident office onsite. The effectiveness of KI as a thyroid protective agent is only slightly reduced if taken shortly after exposure to radioiodine (such as traveling through a release plume on the way to the site). Residents, please store these packets in accordance with the recommendations provided on the label. Please discard any outdated bottles by disposal into a sanitary sewer system.

DOCUMENT NAME: G:\DRS\Work in Progress\Memo 022708 KI Read & Sign.doc

To receive a copy of this document, indicate in the box: "C" = Copy without attachment/enclosure "E" = Copy with attachment/enclosure "N" = No copy

OFFICE	RIII		RIII				
NAME	DSmith:co		EDuncan				
DATE	02/22/08		02/27/08				

OFFICIAL RECORD COPY

Addressees - Memorandum Dated February 27, 2008
Emergency Response Individuals

SUBJECT: FINAL GUIDANCE ON THE USE OF POTASSIUM IODIDE (KI) BY NRC
EMPLOYEES

(Provide to all employees on the ERO roster and any DRP/DRS inspectors.)

C. Acosta	R. Baker	C. Frazier	J. Lara	S. Reynolds
S. Bakhsh	D. Funk	D. Lawver	K. Riemer	
K. Barclay	A. Garmoe	P. Lee	M. Ring	
A. Barker	M. Garza	J. Lennartz	G. Roach	
J. Partleman	R. Gattone	R. Lerch	J. Robbins	
B. Bartlett	J. Gavula	R. Lickus	R. Ruiz	
A. Becker	J. Giessner	C. Lipa	R. Russell	
K. Bernardino	J. Gilliam	D. Lords	J. Rutkowski	
D. Betancourt	K. Gladden	P. Loudon	S. Sarna	
M. Bielby	T. Go	P. Loughheed	M. Satorius	
T. Bilik	M. Gryglak	J. Lynch	D. Schrum	
A. Boland	M. Grzywa	J. Madera	C. Scott	
E. Bonano	L. Haeg	M. Martin	N. Shah	
J. Bozga	G. Hansen	J. Maynen	G. Shear	
S. Brouillard	C. Hausman	M. McCann	S. Sheldon	
C. Brown	G. Hausman	J. McGhee	T. Simmons	
S. Brusehaver	R. Hays	D. McNeil	R. Skokowski	
M. Bucholz	J. Heller	V. Meghani	W. Slawinski	
S. Burgess	C. Hernandez	D. Melendez-Colon	D. Smith	
B. Burgess	P. Higgins	M. Mitchell	W. Snell	
S. Burton	D. Hills	V. Mitlyng	K. Sotiropoulos	
J. Burza	M. Holmberg	C. Moore	G. Stauffer	
R. Butler	B. Holt	M. Morris	T. Steadham	
J. Caldwell	L. Hueter	S. Mulay	K. Stoedter	
J. Cameron	J. Jacobson	M. Munir	A. Stone	
C. Casey	J. Jandovitz	J. Neurauter	R. Stricklin	
J. Cassidy	R. Jickling	R. Ng	D. Szwarc	
G. Christoffer-Baruch	D. Jones	K. Null	J. Tapp	
D. Chyu	L. Jones	K. O'Brien	T. Taylor	
J. Clay	M. Jones	G. O'Dwyer	R. Te	
B. Cushman	R. Jones (DRP)	C. Olteanu	D. Tharp	
A. Dahbur	R. Jones (DNMS)	R. Orlikowski	F. Tran	
R. Daley	B. Jose	S. Orth	C. Scott Thomas	
J. Dalzell	M. Kamprath	B. Palagi	M. Togliatto	
B. Dickson	N. Keller	G. Parker	T. Tomczak	
S. Dombroski	B. Kemker	D. Passehl	F. Tran	
R. Doornbos	M. Kerlin	C. Pederson	N. Valos	
J. Draper	D. Kimble	P. Pelke (EICS)	P. Voss	
E. Duncan	G. Kolcum	P. Pelke (DNMS)	K. Walton	
A. Dunlop	T. Kozak	H. Peterson	G. Warren	
T. Eck	L. Kozak	M. Phalen	S. West	
T. Ehrig	R. Krsek	C. Phillips	D. Wiedeman	
S. Eldridge	M. Kunowski	M. Phillips	M. Wilk	
J. Ellegood	J. Kutlesa	D. Pirok	A. Wilson	
Z. Falevits	P. LaFlamme	D. Piskura	B. Winter	
D. Flowers	M. LaFranzo	F. Ramirez	G. Wright	
N. Feliz	K. Lambert	S. Ray	C. Zoia	
J. Foltz	R. Langstaff	T. Ray	P. Zurawski	
M. Franke	R. Lanksbury	D. Reeser		

**POTASSIUM IODIDE INFORMATION
ACKNOWLEDGMENT FORM**

I hereby acknowledge that I have received the information package concerning the NRC's potassium iodide guidance:

- (1) Memorandum from Roy P. Zimmerman, dated July 3, 2002;
- (2) FDA Guidance - Potassium Iodide as a Thyroid Blocking Agent;
- (3) Summary of Comments on Draft Guidance for Use of Potassium Iodide by NRC Employees, issued December 14, 2001; and
- (4) NRC Use of Potassium Iodide (KI) During an Emergency.

I have also had the opportunity to review the "Region III Incident Response General Overview Training" handout, which is located on the "S:/" drive of the Region III local area network at S:/Incident Response - Training/REGION III GENERAL OVERVIEW TRAINING.

Print Name

Signature _____ Date